In particular, NAC may reverse the severity of liver injury (NASH) in preclinical models of NAFLD by mainly blocking lipid accumulation, through the effective regulation of FFA signaling molecules and transcriptional factors such as SREBP-1c/-2 [44], CD36 [45] and PPARγ [48]. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatohepatitis.